Abstract 135P
Background
Several clinical trials proved neoadjuvant chemoimmunotherapy was considered reliable for stage III non-small-cell lung cancer (NSCLC). Our previous study demonstrated bronchial arterial infusion (BAI) had better efficacy of local control in advanced NSCLC, comparing with chemotherapy. The aim of the study is to confirm efficacy and safety of tislelizumab combined with BAI in stage IIIB NSCLC.
Methods
This single-arm, phase 2 clinical trial enrolled stage IIIB (T3-4N2M0) NSCLC with no EGFR/ALK alterations. All enrolled Pts were considered potentially suitable for complete (R0) resection. Pts received tislelizumab (200mg Q3W, iv) for 3 cycles and BAI Q3W for 2 cycles (docetaxel (75mg/m2) and carboplatin (AUC 5)), followed by surgery within 35 days. Following 2 cycles chemotherapy and tislelizumab maintenance were up to 2 cycles and 1 year duration respectively . The primary endpoint was R0 resection rate, with secondary endpoints including event-free survival (EFS), downstaging rate, objective response rate (ORR), surgery rate, overall survival, major pathological response (MPR), pathological complete response (pCR), and treatment related adverse events (TRAEs).
Results
From January 2023 to September 2024, 24 Pts were enrolled. Median age was 64. 18 Pts were diagnosed with squamous cell lung cancer, and 6 Pts had adenocarcinoma. 20 Pts completed neoadjuvant chemoimmunotherapy and tumor assessment. ORR was 100%, with a complete response (CR) of 25% (5/20) and a partial response (PR) of 75% (15/20). Downstaging rate was 95%, and 18 Pts were suitable for surgical resection (90%). 13 Pts underwent surgical resection including 8 lobectomies, 3 bilobectomies, and 2 pneumonectomies. R0 resection rate was 100%. MPR rate was 84.6% (11/13), and pCR rate was 53.8% (7/13). Median follow-up was 247 days. One-year EFS rate is 80.8%. 15 patients (75%, 15/20) experienced TRAEs. The most common TRAEs were anorexia, myelosuppression, pruritus, and fever. Grade 3 TRAEs occurred in 30% of pts.
Conclusions
Tislelizumab combined with BAI chemotherapy is well tolerated and shows encouraging efficacy compared to retrospective controls.
Clinical trial identification
ChiCTR2300068722.
Legal entity responsible for the study
Shanghai Pulmonary Hospital.
Funding
BeiGene. Ltd.
Disclosure
The authors has declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
Resources:
Abstract
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
Resources:
Abstract
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
Resources:
Abstract
36P - Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Luigi Liguori
Session: Poster Display session
Resources:
Abstract
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
Resources:
Abstract
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
Resources:
Abstract
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
Resources:
Abstract
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
Resources:
Abstract
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract